S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   326.01 (-0.11%)
AAPL   139.35 (+1.81%)
MSFT   226.55 (+0.70%)
FB   275.10 (+0.82%)
GOOGL   1,896.53 (+0.66%)
AMZN   3,294.73 (-0.37%)
TSLA   847.19 (+0.26%)
NVDA   548.71 (-1.08%)
BABA   258.66 (-0.52%)
CGC   33.86 (+0.89%)
GE   11.13 (+0.54%)
MU   82.48 (-2.98%)
AMD   92.91 (+1.51%)
NIO   61.96 (+6.21%)
T   29.02 (+0.66%)
F   11.51 (-0.17%)
ACB   10.66 (-4.57%)
BA   206.01 (-0.67%)
DIS   172.82 (+0.90%)
NFLX   565.33 (-2.50%)
GILD   67.13 (+0.22%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   326.01 (-0.11%)
AAPL   139.35 (+1.81%)
MSFT   226.55 (+0.70%)
FB   275.10 (+0.82%)
GOOGL   1,896.53 (+0.66%)
AMZN   3,294.73 (-0.37%)
TSLA   847.19 (+0.26%)
NVDA   548.71 (-1.08%)
BABA   258.66 (-0.52%)
CGC   33.86 (+0.89%)
GE   11.13 (+0.54%)
MU   82.48 (-2.98%)
AMD   92.91 (+1.51%)
NIO   61.96 (+6.21%)
T   29.02 (+0.66%)
F   11.51 (-0.17%)
ACB   10.66 (-4.57%)
BA   206.01 (-0.67%)
DIS   172.82 (+0.90%)
NFLX   565.33 (-2.50%)
GILD   67.13 (+0.22%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   326.01 (-0.11%)
AAPL   139.35 (+1.81%)
MSFT   226.55 (+0.70%)
FB   275.10 (+0.82%)
GOOGL   1,896.53 (+0.66%)
AMZN   3,294.73 (-0.37%)
TSLA   847.19 (+0.26%)
NVDA   548.71 (-1.08%)
BABA   258.66 (-0.52%)
CGC   33.86 (+0.89%)
GE   11.13 (+0.54%)
MU   82.48 (-2.98%)
AMD   92.91 (+1.51%)
NIO   61.96 (+6.21%)
T   29.02 (+0.66%)
F   11.51 (-0.17%)
ACB   10.66 (-4.57%)
BA   206.01 (-0.67%)
DIS   172.82 (+0.90%)
NFLX   565.33 (-2.50%)
GILD   67.13 (+0.22%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   326.01 (-0.11%)
AAPL   139.35 (+1.81%)
MSFT   226.55 (+0.70%)
FB   275.10 (+0.82%)
GOOGL   1,896.53 (+0.66%)
AMZN   3,294.73 (-0.37%)
TSLA   847.19 (+0.26%)
NVDA   548.71 (-1.08%)
BABA   258.66 (-0.52%)
CGC   33.86 (+0.89%)
GE   11.13 (+0.54%)
MU   82.48 (-2.98%)
AMD   92.91 (+1.51%)
NIO   61.96 (+6.21%)
T   29.02 (+0.66%)
F   11.51 (-0.17%)
ACB   10.66 (-4.57%)
BA   206.01 (-0.67%)
DIS   172.82 (+0.90%)
NFLX   565.33 (-2.50%)
GILD   67.13 (+0.22%)
Log in
NASDAQ:SRDX

Surmodics Stock Forecast, Price & News

$46.10
+1.35 (+3.02 %)
(As of 01/22/2021 03:57 PM ET)
Add
Compare
Today's Range
$44.54
Now: $46.10
$46.10
50-Day Range
$38.24
MA: $41.54
$45.99
52-Week Range
$22.06
Now: $46.10
$49.00
Volume1,403 shs
Average Volume55,222 shs
Market Capitalization$630.74 million
P/E Ratio576.25
Dividend YieldN/A
Beta1
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The Vitro Diagnostics segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Surmodics logo

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

381st out of 1,922 stocks

Surgical & Medical Instruments Industry

34th out of 168 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000
Employees370

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$94.86 million
Cash Flow$0.68 per share
Book Value$9.63 per share

Profitability

Net Income$1.12 million

Miscellaneous

Market Cap$630.74 million
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$46.10
+1.35 (+3.02 %)
(As of 01/22/2021 03:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Surmodics (NASDAQ:SRDX) Frequently Asked Questions

How has Surmodics' stock been impacted by COVID-19 (Coronavirus)?

Surmodics' stock was trading at $29.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRDX stock has increased by 53.3% and is now trading at $45.86.
View which stocks have been most impacted by COVID-19
.

Is Surmodics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Surmodics stock.
View analyst ratings for Surmodics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Surmodics?

Wall Street analysts have given Surmodics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Surmodics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Surmodics' CEO?

1,448 employees have rated Surmodics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Surmodics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Surmodics' next earnings date?

Surmodics is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Surmodics
.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) announced its earnings results on Wednesday, November, 4th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.19. The business had revenue of $22.54 million for the quarter, compared to the consensus estimate of $21.67 million. Surmodics had a net margin of 1.18% and a return on equity of 1.42%.
View Surmodics' earnings history
.

What price target have analysts set for SRDX?

3 brokers have issued twelve-month price objectives for Surmodics' stock. Their forecasts range from $61.00 to $76.00. On average, they expect Surmodics' stock price to reach $66.67 in the next year. This suggests a possible upside of 45.4% from the stock's current price.
View analysts' price targets for Surmodics
or view Wall Street analyst' top-rated stocks.

Who are some of Surmodics' key competitors?

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

Who are Surmodics' key executives?

Surmodics' management team includes the following people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 57, Pay $1.13M)
  • Mr. Timothy J. Arens, Sr. VP of Fin. & Information Technology and CFO (Age 53, Pay $509.4k)
  • Ms. Teryl L. W. Sides, Sr. VP of Product Devel. & Chief Marketing Officer (Age 51, Pay $538.71k)
  • Mr. Joseph J. Stich, Sr. VP & GM of HR - In Vitro Diagnostics (Age 55, Pay $508.75k)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 54, Pay $523.6k)
  • Mr. John D. Manders, Corp. Controller & Principal Accounting Officer (Age 39)
  • Mr. Gordon S. Weber, Sr. VP of Legal, Gen. Counsel & Sec. (Age 57)
  • Mr. Charles W. Olson, Sr. VP of Commercial & Bus. Devel. - Medical Devices (Age 56)
  • Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 60)

What is Surmodics' stock symbol?

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.43%), State of Alaska Department of Revenue (0.08%) and Diversified Trust Co (0.04%). Company insiders that own Surmodics stock include Gary R Maharaj, Joseph J Stich and Lisa Wipperman Heine.
View institutional ownership trends for Surmodics
.

Which major investors are selling Surmodics stock?

SRDX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Surmodics company stock in the last year include Gary R Maharaj, and Joseph J Stich.
View insider buying and selling activity for Surmodics
or view top insider-selling stocks.

Which major investors are buying Surmodics stock?

SRDX stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, and Diversified Trust Co.
View insider buying and selling activity for Surmodics
or or view top insider-buying stocks.

How do I buy shares of Surmodics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Surmodics' stock price today?

One share of SRDX stock can currently be purchased for approximately $45.86.

How big of a company is Surmodics?

Surmodics has a market capitalization of $627.46 million and generates $94.86 million in revenue each year. The company earns $1.12 million in net income (profit) each year or $0.13 on an earnings per share basis. Surmodics employs 370 workers across the globe.

What is Surmodics' official website?

The official website for Surmodics is www.surmodics.com.

How can I contact Surmodics?

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.